A common base of WHO-GMP and PIC/S certified plants puts most molecules within reach of several suppliers at once. Registration is the one part of the sequence a buyer cannot compress at the point demand appears.
Basis: registrations in force as at 2 September 2026. One SKU is one molecule, strength and form filed with one authority.
Priority molecules are selected from a range of 2,186, filed with the authority in CTD format, and supported by the COPP and the plant-level WHO-GMP and PIC/S certificates behind each one. In the four markets above, the authority's format, its queries and the evidence it expects are established from earlier submissions. In a market not yet entered, the first dossier establishes them, and the timeline belongs to the authority.
Basis: trading range as at 26 August 2026, gross of all therapy categories.
What is already registered in your market, who supplies it today, and where demand is going unmet.
Your priority molecules filed with your authority, from sites holding current WHO-GMP or PIC/S certification.
Against a registration in force.
Aravis holds no product registrations in either region. Sourcing plants carry accreditations from 22 national and regional authorities across four regions, 12 of them African and 2 in the Middle East, so a first filing into one of those markets begins from a site the regulator has already inspected. The registration itself has yet to be filed.
Basis: plant accreditations held by sourcing partners as at 26 August 2026. Aravis product registrations are the four markets above.
The full accreditation footprint, and the authorities behind it, sit under Capabilities.
Tell us the market and what you stock. Aravis establishes what is registered and moving there, sets it against a range of 2,186 molecules, and returns the molecules worth filing in priority order with the documentation route for each.
We review every enquiry and respond where there is a portfolio fit.